ORGS
Orgenesis IncPINK
Healthcare • Biotechnology
Updated 9 days ago
Coverage limited
$2.11-34.84%
Close Oct 18, 2024
- Market cap
- —
- 1 month
- -65.5%
- 3 months
- -73.3%
- 1 year
- -79.0%
- Dividend
- No dividends on record
- Short interest
- 0.1% of float5.3K shares · settled Sep 30, 2026 · 0.0% since Sep 15, 2026 · FINRA
Fundamentals · trailing 12 months to Dec 31, 2024
- Revenue
- $1.04M
- Net income
- -$29.93M
- Free cash flow
- -$17.34M
- Book value
- —
- Total debt
- $8.22M
- P/E
- —
- Price / sales
- —
- Price / book
- —
- FCF yield
- —
- Net margin
- -2,891.3%
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Portfolio context
Sign in to see your position size
We’ll show you if ORGS is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
Smart money context
Holder IQ: HIGH
1 top institutions tracked
as of 2026-Q2 (filed 2026-09-10)
Last 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: unknown
No recent insider trades detected.
Red flags: 0
Largest 13-F holders · Q2 2026
1 filers reported a long position in ORGS for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| Knoll Capital Management, LLC | $20.8K | 50.6K | Unchanged |
Get the Full Analysis for ORGS
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.